Keyword: The Bill & Melinda Gates Foundation
As we near the end of the year, we take a look back over the biggest stories of 2018 and gauge what readers found the most interesting.
Two years after its founding, Biomatics Capital Partners has raised $300 million for its second fund and signed on two new venture partners.
The Gates Medical Research Institute will turn drug industry expertise on diseases that kill millions annually in low- and middle-income countries.
The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.
The Bill & Melinda Gates Foundation is investing up to $40 million spur research into the use of TCR-based therapeutics to treat tuberculosis and HIV.
Lundbeck chief Schultz will lead Teva, former CDC director Frieden leads a new health project, Roivant named Eisai exec Waxman as general counsel.
Vir Biotechnology focuses on developing vaccines and drugs to cure infectious diseases for which there are currently scarce treatments. Though it hasn’t provided any details about its pipeline quite yet, its launch was remarkable for the sheer size of the funding: $150 million from ARCH Venture Partners.
Infectious disease specialist Arsanis has raised a solid chunk of cash as it picks up the Gates Foundation and Alphabet's GV as backers.
Intarcia has raised $206 million in a second close of its Series EE financing, with the Bill & Melinda Gates Foundation pitching in a $50 million investment and up to $90 million in potential milestones, the company announced on Thursday.
Sydney-based Atomo Diagnostics picked up AU$4.5 million ($3.5 million) in equity from a number of investors, including the Gates Foundation-backed Global Health Investment Fund.